Pacira Pharmaceuticals (PCRX) Has Upside as EXPAREL Roll-Out Kicks into Gear - Wedbush
Tweet Send to a Friend
Today Wedbush reiterated an Outperform rating and $18 price target on Pacira Pharmaceuticals (NASDAQ: PCRX).
Analyst Richard Lau ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst Richard Lau ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
